Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice.
作者信息
Lerrer Shalom, Mor Adam
机构信息
Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY, USA.
出版信息
Transl Cancer Res. 2019 Dec;8(Suppl 6):S625-S627. doi: 10.21037/tcr.2019.07.43.
Abstract
摘要
相似文献
1
Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice.免疫检查点抑制剂与共同表位理论：从假说到实践
Transl Cancer Res. 2019 Dec;8(Suppl 6):S625-S627. doi: 10.21037/tcr.2019.07.43.
2
Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review.除远隔效应外，提高癌症免疫检查点抑制剂疗效的策略：一项系统综述
Cancers (Basel). 2019 Apr 15;11(4):539. doi: 10.3390/cancers11040539.
3
Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice.肝细胞癌免疫检查点抑制剂治疗概述，以及ITA.LI.CA队列得出的临床实践中免疫检查点抑制剂适用率估计值。
Cancers (Basel). 2019 Oct 30;11(11):1689. doi: 10.3390/cancers11111689.
4
T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.WAP-T小鼠乳腺癌中的T细胞表位强度是PD1/PD-L1免疫检查点阻断疗法的一个重要决定因素。
Oncotarget. 2016 Oct 4;7(40):64543-64559. doi: 10.18632/oncotarget.11620.
5
Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors.肿瘤适应性、免疫衰竭与临床结局：免疫检查点抑制剂的影响。
Sci Rep. 2020 Mar 19;10(1):5062. doi: 10.1038/s41598-020-61992-2.
6
Rare, but Severe: Vasculitis and Checkpoint Inhibitors.罕见但严重：血管炎与检查点抑制剂。
Eur Urol Focus. 2020 May 15;6(3):609-612. doi: 10.1016/j.euf.2019.04.014. Epub 2019 May 6.
7
The association of HLA-DRB genes and the shared epitope with rheumatoid arthritis in Pakistan.巴基斯坦人群中HLA - DRB基因及共同表位与类风湿性关节炎的关联。
Br J Rheumatol. 1997 Nov;36(11):1184-8. doi: 10.1093/rheumatology/36.11.1184.
8
Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.晚期黑色素瘤中的检查点抑制剂：对免疫治疗领域的影响。
Expert Rev Anticancer Ther. 2017 Jul;17(7):647-655. doi: 10.1080/14737140.2017.1341315. Epub 2017 Jun 19.
9
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.非小细胞肺癌免疫检查点抑制剂的作用机制及潜在预测生物标志物。
Biomed Pharmacother. 2020 Jul;127:109996. doi: 10.1016/j.biopha.2020.109996. Epub 2020 May 6.
10
Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way.免疫疗法治疗内分泌恶性肿瘤：免疫检查点抑制剂引领潮流。
Endocr Relat Cancer. 2017 Dec;24(12):T261-T281. doi: 10.1530/ERC-17-0222. Epub 2017 Sep 11.
引用本文的文献
1
Benefits from standalone durvalumab treatment in an elderly patient with advanced prostatic sarcoma: a case report.度伐利尤单抗单药治疗老年晚期前列腺肉瘤患者的疗效：一例报告
Transl Androl Urol. 2021 Nov;10(11):4298-4303. doi: 10.21037/tau-21-125.
2
A novel mouse model for checkpoint inhibitor-induced adverse events.一种用于检查点抑制剂诱导的不良反应的新型小鼠模型。
PLoS One. 2021 Feb 11;16(2):e0246168. doi: 10.1371/journal.pone.0246168. eCollection 2021.
3
Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction.低蛋白血症是免疫治疗相关肝功能障碍的一种表现。
Ann Transl Med. 2020 Jul;8(14):889. doi: 10.21037/atm-20-4980.
本文引用的文献
1
Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach.免疫检查点阻断相关免疫相关不良事件的机制：利用种系遗传学制定个体化方法。
Genome Med. 2019 Jun 20;11(1):39. doi: 10.1186/s13073-019-0652-8.
2
Application of PD-1 Blockade in Cancer Immunotherapy.PD-1阻断剂在癌症免疫治疗中的应用。
Comput Struct Biotechnol J. 2019 May 23;17:661-674. doi: 10.1016/j.csbj.2019.03.006. eCollection 2019.
3
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.癌症免疫治疗后的不良反应：挑战与机遇。
Trends Immunol. 2019 Jun;40(6):511-523. doi: 10.1016/j.it.2019.04.002. Epub 2019 Apr 30.
4
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.非小细胞肺癌中检查点抑制剂诱导的毒性作用与共享的癌症和组织抗原的关系。
JAMA Oncol. 2019 Jul 1;5(7):1043-1047. doi: 10.1001/jamaoncol.2019.0402.
5
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade.程序性死亡受体1（PD-1）免疫检查点抑制剂与免疫相关不良事件：了解检查点阻断的负面影响中的积极一面
JAMA Oncol. 2019 Jul 1;5(7):942-943. doi: 10.1001/jamaoncol.2019.0413.
6
Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors.癌症患者接受免疫检查点抑制剂治疗的免疫相关不良反应。
Curr Rheumatol Rep. 2018 Sep 6;20(10):65. doi: 10.1007/s11926-018-0770-0.
7
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors.T细胞交叉反应性或许可以解释癌症患者对检查点抑制剂反应的巨大差异。
Scand J Immunol. 2018 Mar;87(3). doi: 10.1111/sji.12643.
8
Inhibitors of the PD-1 Pathway in Tumor Therapy.肿瘤治疗中的 PD-1 通路抑制剂。
J Immunol. 2018 Jan 15;200(2):375-383. doi: 10.4049/jimmunol.1701044.
Zotero 插件